SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias early third-quarter report and raised full-year revenue guidance are driving attention, with continued LUPKYNIS sales growth supporting the results. Traders are split between viewing the report as solid execution and frustration that the shares fell despite it, compounded by confusion over whether management held an earnings call.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Attention centers on Alpha Taus oncology pipeline, particularly the FDA-cleared expansion of its REGAIN glioblastoma trial and upcoming clinical updates, alongside completed enrollment in its pancreatic-cancer IMPACT study. Traders are broadly bullish on the catalyst pipeline, though some are waiting for larger-cohort data to confirm the early results.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys quarterly results, particularly resilient parks performance and improving streaming profitability, have reinforced bullish sentiment and prompted analyst upgrades. Traders remain divided, with some seeing a turnaround while others point to the stocks long stretch of weak, range-bound performance.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is pulling back after a strong run as traders position ahead of earnings, with some wary of recent SaaS-sector weakness and the stocks valuation. Others remain bullish on growth and AI-driven commerce, while security concerns appear in some bearish posts but are not the dominant discussion.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Attention centers on Candels planned BLA submission for CAN-2409 in localized prostate cancer and upcoming SITC presentations of clinical and biomarker data. The community is split between optimism about the Phase 3 results and approaching milestones and concern over the stocks decline, the CEOs share sale, transparency, and potential dilution.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

ALAB is drawing attention amid a sharp pullback alongside other AI and semiconductor stocks, with traders citing stretched valuations, broad market pressure, and uncertainty ahead of earnings. The community is split between buyers treating the decline as an opportunity and bears warning that the stock remains overvalued and could fall further.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

ARKK fell with a broader selloff in tech and other risk-sensitive assets, while traders criticized the funds weak performance and Cathie Woods stock-picking and portfolio changes. Some participants viewed the decline as a buying opportunity or pointed to bullish chart setups, but bearish commentary was prominent.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels weak fourth-quarter outlook after earnings, amid softer PC demand and manufacturing constraints, triggered a steep selloff and analyst downgrades. Traders are divided between calling the decline an overreaction and buying the dip, and seeing it as evidence of deeper execution and turnaround problems.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF

JEPQ is drawing attention around its monthly distribution and ex-dividend schedule as Nasdaq weakness weighs on the ETF. Traders are focused on the income and buying the dip, while others note that its covered-call strategy can cushionbut not preventlosses and may limit upside in a rebound.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys shares are drawing attention after a sharp post-earnings rally despite revenue and EPS misses; traders are focusing on premium subscriber growth, stronger gross margin, and an upbeat fourth-quarter profit outlook. The move has surprised some investors, who question why the stock rose on a mixed report, while bulls see the guidance and improving ad revenue as the more important signals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings Growth

Zymeworks (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors

Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced the appointment of Adam Schayowitz, Ph.D., MBA, to its Board of Directors. Dr. Schayowitz is Executive Vice President and Head...

Stocktwits Biotech Dealmaker: Gilead And Roche Double Down On Early-Stage Assets Over Full Buyouts This Week

Equity

Inflammation, cancer therapies called antibody-drug conjugates, and next-generation T-cell engagers with possibilities in treating cancer drew the biggest capital in the relatively slow week for biotech dealmaking. 

Zymeworks Issues Updated 2026 Financial Guidance

(RTTNews) - Zymeworks (ZYME) said the company now expects total revenue for 2026 to be between $278 million and $292 million and 2026 adjusted EBITDA to be between $114 million and $128 million, excluding the impact of any future transactions. The company announced the updated fi...

JAZZ Rises on Updated OS Results From Gastric Cancer Study

Jazz up as updated HERIZON-GEA-01 results show statistically significant OS benefits for Ziihera-based regimens in first-line HER2+ gastroesophageal adenocarcinoma.

SJM, ZYME Stocks Hit 52-Week High – What’s Driving The Surge Today?

SJM raised its annual outlook following a quarterly earnings beat, while ZYME gained on price-target hikes tied to Ziihera’s FDA approval.

JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer

Jazz Pharmaceuticals' Ziihera wins FDA approval for first-line HER2-positive GEA, expanding its market and showing strong progression-free and survival benefits.

JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy

The FDA approved Jazz Pharma’s Ziihera with chemotherapy, with or without BeOne’s Tevimbra, as an initial treatment for advanced HER2-positive gastroesophageal cancer.


TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks

Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.

Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates

Zymeworks (ZYME) delivered earnings and revenue surprises of -10.71% and +25.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Zymeworks BC Inc

Bearish Sentiment

<ul class="summary-bullets"><li><a class="mention" data-mention="$GILD" data-symbol-id="GILD" href="https://stocktwits.com/symbol/GILD" target="_blank">Gilead Sciences</a> agreed on Thursday to buy Shanghai-based PepStar Therapeutics’ experimental oral drug program for inflammatory diseases.&nbsp;</li><li>Roche gained exclusive global rights to Zymeworks’ ZW209 in a deal worth up to $813 million plus royalties.</li><li>Roche and Hansoh Pharma also expanded their antibody-drug conjugate partnership in a deal that could exceed $15 billion in total value.</li></ul><p>Large drugmakers continued to favor targeted asset purchases and licensing deals for early-stage, differentiated candidates rather than full company acquisitions this week, implying a shift from earlier this year, when full-scale acquisitions dominated the sector.</p><p>Inflammation, cancer therapies called antibody-drug conjugates, and next-generation T-cell engagers with possibilities in treating cancer drew the biggest capital in the relatively slow week for biotech dealmaking, as companies sought to fill specific pipeline gaps. The sole exception was Merck KGaA’s roughly $1.3 billion purchase of Silence Therapeutics.</p><h2 class="st-heading-2">Gilead Acquires Oral Drug Program For $1.275B</h2><p>Gilead Sciences (GILD) agreed on Thursday to buy Shanghai-based PepStar Therapeutics’ experimental oral drug program for inflammatory diseases, including its lead candidate HCXT-2001, for $1.275 billion in cash.</p><p>Gilead sees potential to develop the early-stage asset alone or in combination with its own oral drug emvistegrast as an all-oral approach for inflammatory bowel disease. The deal is expected to close in the fourth quarter and gives Gilead worldwide rights. The deal comes as part of Gilead’s efforts to expand its inflammation portfolio beyond its core HIV business and follows a mid-October collaboration deal with Vir Biotechnology.</p><h2 class="st-heading-2">Roche Licenses Zymeworks' Drug For Lung Cancer</h2><p>U.S.-listed shares of Switzerland-based Roche (RHHBY) gained exclusive global rights to Zymeworks’ (ZYME) ZW209 in a deal worth up to $813 million plus royalties. Zymeworks will receive $55 million upfront and $40 million upon initiation of a Phase 1b trial, with eligibility for up to $718 million in additional development, commercial, and sales milestones, plus tiered high-single-digit to mid-teen royalties.</p><p>Zymeworks will run the Phase 1a monotherapy study with Roche funding, after which Roche takes over global development and commercialization. The candidate targets DLL3, a protein commonly expressed on small-cell lung cancer cells.</p><h2 class="st-heading-2">Roche Expands ADC Collaboration With Hansoh</h2><p>Roche and China-based pharmaceutical company Hansoh Pharma also expanded their antibody-drug conjugate (ADC) partnership in a deal that could exceed $15 billion in total value. Hansoh will receive $400 million upfront and $110 million on the first anniversary, plus eligibility for more than $15 billion in development, regulatory, and commercialization milestones, along with royalties.</p><p>The collaboration covers two preclinical Hansoh ADC programs and multiple additional programs against Roche-selected targets using Hansoh’s platform. Hansoh will lead development through global Phase 1a trials. Roche then takes over worldwide development outside Greater China, where Hansoh retains rights. The agreement builds on a prior single-asset ADC partnership and underscores Roche’s continued push into next-generation ADCs across multiple cancer types.</p><h2 class="st-heading-2">Merck KGaA To Acquire Silence Therapeutics For $1.3B</h2><p>Merck KGaA on Monday agreed to acquire Silence Therapeutics (SLN) in an all-cash deal with an equity value of approximately $1.3 billion. The German drugmaker will pay $20 per American Depositary Share, representing a roughly 130% premium to the stock’s close before the deal announcement.</p><p>The main prize is divesiran, a late-stage-ready therapy for a rare blood cancer. The transaction is expected to close in the first quarter of 2027 and adds both a late-stage rare-disease asset and RNA technology to Merck’s pipeline.</p><p>On Stocktwits, retail sentiment around GILD was 'neutral' at the time of writing, while sentiment around RHHBY, ZYME, and SLN was 'bullish' or 'extremely bullish.'</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/space-x-s-80-000-cell-site-push-a-win-for-asts-ericsson-nokia-next-nav-among-others-says-roth-capital/cZxywyDRBUI">SpaceX’s 80,000 Cell Site Push A Win For ASTS, Ericsson, Nokia, NextNav, Among Others, Says Roth Capital</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;</p>

Digital background depicting innovative technologies in medicine systems, neural interfaces and research genetic and biology. Source: Getty Images

Gilead Sciences, Inc.

Roche Holdings AG ADR

Zymeworks Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

ZYME News